Scale up smarter: Simulation for pharmaceutical process design and tech transfer

Pharmaceutical process development is under pressure. R&D ROI has fallen from 6.5% in 2014 to 1.2% in 2022, and only 1 in 5,000 drug candidates ever reaches market approval. Bringing a new treatment to patients costs between 2.6 billion and 6.7 billion USD. This infographic breaks down why traditional approaches are no longer enough and how simulation is redefining the path from lab to production.

The cost of getting it wrong

Traditional process design relies on time-consuming physical trials, limited equipment testing and siloed data that slows decision making. Without a connected view across formulations, fluid dynamics and process simulation, scale-up errors compound, timelines stretch and costs spiral. The gap between discovery and commercial manufacturing has never been more expensive to close.

A smarter path to production

Simcenter™ solutions from Siemens offer a comprehensive digital thread that connects every stage of pharmaceutical process design through an integrated Digital Twin (a virtual replica of the physical manufacturing process). From formulations and process development to heat and mass transfer, particle flow behavior and executable Digital Twins, the platform enables virtual scale-up, faster tech transfer and confident, data-driven decisions before a single physical run is made.

The result: higher productivity, reduced costs and faster delivery of life-changing therapies.

Download the infographic

Discover how AI-powered simulation and Digital Twin technology help pharma teams reduce scale-up costs, accelerate tech transfer and improve R&D ROI.